Business UpdateJun 1, 2026, 04:05 PM
Fulcrum Discontinues Pociredir Program; Initiates Strategic Review
AI Summary
Fulcrum Therapeutics announced the discontinuation of its pociredir program for sickle cell disease following FDA feedback on potential malignancy risks, linking it to the global withdrawal of Tazverik®. The FDA concluded that all PRC2 complex inhibitors carry equivalent malignancy risk, leaving no viable regulatory path for pociredir. Consequently, Fulcrum has initiated a comprehensive review of strategic alternatives to maximize stockholder value and will significantly reduce operating expenses.
Key Highlights
- Discontinued pociredir program for sickle cell disease.
- FDA cited malignancy risk concerns with PRC2 inhibitors.
- Initiated comprehensive review of strategic alternatives.
- Will significantly reduce operating expenses and preserve capital.
- Held $333.3 million in cash as of March 31, 2026.
Price Impact
More from FULC